Dr. Jerome Anthony Quinn, D.P.M Podiatrist Medicare: Not Enrolled in Medicare Practice Location: 80 Morgan Branch Rd, Weaverville, NC 28787 Phone: 828-658-0777 Fax: 828-658-1992 |
News Archive
Rhythm announced today the results of two Phase 1 clinical trials of RM-131, the company's novel ghrelin agonist for the treatment of diabetic gastroparesis, which demonstrated that RM-131 greatly accelerates gastric emptying in healthy subjects with good tolerability.
TomoTherapy Incorporated announced today that it will host an analyst and investor presentation in conjunction with the annual ASTRO (American Society for Radiation Oncology) meeting on Monday, Nov. 2, 2009, at 8:00 a.m. CT.
According to Millennium Research Group (MRG), the global authority on medical technology market intelligence, embolization particles will show the most significant growth, both in procedure volume and in revenue, among all devices in the transcatheter embolization and occlusion (TEO) market. Radioembolization is expected to grow from $50 million in sales in 2011 to $128 million in 2015, while drug-eluting beads will grow from $11 million to $28 million over the same period.
A study carried out by researchers from the Department of Radiology and Physical Medicine of the University of Granada, in collaboration with the Andalusian School of Public Health (Escuela Andaluza de Salud Publica), found that 100% of Spaniards analyzed had at least one kind of persistent organic compound (POC's), substances internationally classified as potentially harmful to one's health, in their bodies.
​Stroke patients who participate in a cardiac rehabilitation program for six months make rapid gains in how far and fast they can walk, the use of weakened limbs and their ability to sit and stand, according to a study presented today at the Canadian Stroke Congress.
› Verified 3 days ago